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Alt ho u ~ h

~ G nsequence

a few

this

r 2po r ts have

a~ti-enz y~a t i c

ttolo c ic zparin r of
as partl y

~isp ~~2ta

eff ect.

c~t0ch0lamines ,

r e spo ~ slbl 0

bee~

a~ d

t c s been

pub lished tc

the resultqnt
~ncri~inated

f e r t h e hypersansltivtty of

~yper-

actions of sympattomimetic amines.
nather recently a cl a ss of anti-melancholy druITs, or
:'psyc h ic e ner e; izers", have been maCie clinically available.

These agents seem to act a s anti-depressants by virtue of
their mono amine oxidase antagonizing properti.1:0 s .
It was strange, theref ore, to note in the literatur e

that a clinical psychotherapeutic incompatibility existed
between concurrent thy .ro i d and monoami ne oxi c!ase
medication.

in~

U_; i tor

Peculiar changes in thyroia function, bloo d

pressure, and blood g lucose levels were also
with the latter med!caments.

noto~

cl1.nicall y

The present research was

unr1ertaken, uslng bloo rl : :i: 1.ucose. blood pressure. and acute
and subacute toxicj.ty studies as parameters. to evaluate

:t v

thesa paradoxical reports.

Male, albino rats were employed

as sutjects.
Two che:dcally diss1.milar, irreversibly

actin~,

monoamine

oxidase inhibitors, ip2on iazid (11ars i lid) and M0-911, were
selected as test compounds.

'l1 he de. i ly intra.per i tonea.l

(175 mg/kg) and M0-911 (10 and 25

injection of iproniazid

mg/kg) for a three week period elicited only inconsequent';.al

blood sugar changes in both cuthyroid and hyperthyroid animals.
Systolic pressures became

si~nif icantly

elevated upon continued

injection of either dru3, and the presser effects were enhanced
by feeding a 2

i

thyroi d diet.

Limitej dopamine excretion stud 1.es i.n hyperthyroid rats
revealad no particular changes, whereas massive. daily doses
of ipronlazi'.1 provol.ced

ir~crea2.ed

approximately 200 to 300
inhibitor treatment.

]~

excretion of the catecl-:.o lamine

after fifteen days of enzyme

These urinary results did not parall0l

the hypertensive effects.
Weight loss, sluggishness, and gross and microacoplc
evidence of vital organ damage occurred with massive, daily
doses of iproniazid.

The acute lethal effects of M0-911 were

augmented by thyroid feeding.
These results seem to suggest strongly that the direct
and indirect pharmacologic actions of iproniazid and M0-911,
given in hlgh daily doses to l"ats, are age;ravated by a hyperthyroid state; these experimental finnings have obvious
clinical significance.
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INTRODUCTION
Accumulating evidence seems to indicate that the feeding
of thyroid extract, or the parenteral administration of
thyroxine, produces a decline in the monoamine oxidase
activity of various animals.

This anti-enzymatic effect may

result in a biological sparing of catecholamines which
might be partly responsible for the hypersensitivity of
hyperthyroid animals and isolated tissues to the pharmacologic
actions of sympathomimetio amines.

It has been shown that

monoamine oxidase is intimately involved in catecholamine
metabolism and that its inhibition can alter the circulating
levels of various pressor and glycogenolyt1c amines.
Recently a class or anti-melancholy drugs or "payohio
'

energizers" has been introduced for clinical use.

These

.

compounds appear to act as anti-depressants by virtue of
their ability to irreversibly inhibit monoamine oxi4ase
activity.

The clinical use or these substances

~•e

known

to cause a noticeable elevation in the mood of depressed
subjects.
Other recent evidence has been presented in the literature
which indicates that a clinical psyohotherapeutic incompatibility exists with the concurrent thyroid and anti-melanohol7
monoamine oxidase inhibitor medication.

Peculiar changes

5

in thyroid function, blood pressure and blood glucose levels
such as orthostatic hypotension and hypoglycemia were also
noted clinically with mf!.Q.Yof the latter medicaments.
Such evidence indicates that a close relationship exists
between the

~

!..!.!2, activity of the thyroid hornione s.n d ot

the enzyme monoan1ino oxidaae, and that when the activitfe8for
these substances are simultaneously altered a variety of
peculiar effects a1u elicited.
The

p~esent

research was undertaken to evaluate some of

the possible effects of concurrent administration ot both
desiccated thyroid and monoamine oxidase inhibitors in
laboratory rodents.

Blood glucose, blood proesure, and

acute and aubaoute toxicity studies were employed as
parameter1.

~~ lement r-:.1

io >lne

i · H. J

into med :l.c l ne

<;ff i c ia l ly in t r o ,~ uced

believed that the Chlne es, many centuries before the birth
of Ct r "ist,

~· ,,;,:i

leePne~l

t-t"' nt c er tatn S'.J tstar.ces, presently
8 ~\ SI' t c: .J

!tnov-m to cont.a.in iod lne.

bene.t ic ia l effects tn tbis

iodine in the m::nr:mal.iar: :-Jody was fourd. in the tl::;rrot d e:l. nnd

aud that it was firmly bound
material.

Oswald later identified this as a pro t0in aari

named it thyroglobuli.n.
..,,.,al"l

r.~,,_
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l··
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whic ~

a·:::tlve in hypothyroid patients; it was

~as

a

therepe u ttne lly

terrn~·5

Later Harington (1926) id en t ified thyroxine ct

l:t: ~yr' ::ixinr:;,

~

ierlvattve
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Significant advances have

a15G been made in the chemistry and physiology of the thyro td

stimulating hormone (TSH) (White, 1946; Albert, lq4g; Rawson,
19~G;

Harris and Woods,

1947; Nelson and Bradley, 1960;

Sonenberg and Money, 1960;

Car~ten

in tho desc1"iptton of the rol(::

l9S7j Greer et

end Wynston 1 1960), and

thenervcu ~

system. plays 1n

Unfortunatelyf the mechanism of

action of thyroxine and its analo?ues has not yet been clearly
definedo

Blood borne thyroxine can

be

converted to

triiodothyronine ( TRIT) in the thyro idectomtzed rat (Gross
and Leblond, 1951) and human (Pitt-Rivers!! aL, 1955),
and there ts some evidence to indicate that thts conversion

may be an essential step in forming the ''active" hormone
(Lardy et aL,

1957).

A number of' compounds have been

implicated as the peripherally acting hormone.

TRIT is

wlthout question, at least in mammals, the more rapid
acting (Barker, 1956,1957), and with chronic dosage, the
more potent (Gross and Pitt=Rivers, 1954; Roche and Michel 1

1955).

Several acetyl derivatives of thyroxine, viz",

tetraiodothyroacetic acid (T3TRAC) anrl triiodoacetic acid

(TRIAC) have recently been isolated, they are less active
biologically than thyroxine or TRIT (Trotter,

1955~

Goolden,

8

1956).

However, the actual chem:ioal entity responsible for

the observed hormonal effects still remains controversial.
It is thought that thyroid analoBues may act directly
or indirectly on the enzymatic activity of nervous tissue as
they do on somatic tissues.

This is

significa~t

as many facets

of brain chemistry and metabolism are now being extensively
studied.

Recent investigators have outlined the possible

metabolic pathways for the synthesis of dopamine, epinephrine
{E), and nnorQinephrine (NE), catecholamines which a.re found
extensively in nervous tissue.

It is

notewort~y

in this

respect that 1-tyrosine is the amino Heid precursor of' thyroxine
as well as of the catecholamines (Blaschko, 1959).
In order to

underst~~d

the manifold enzymatic effects

of the thyroid hormone, investigators have delved into the
cellular metabolism of the hormone itself.

Such studies

have shown that there are three possible pathways for the
metabolism of the iodothyronines: dehalogenation, oxidation
o:f the alanine chain, and esterifica.tion or the phenolic
group (Lissitzky and Bouchilloux, 1957; Roche and Michel,
1960).

It is also believed that the iodothyronines are

oxidatively deaminated to give a keto acid which is
subsequently decarboxylated to give the corresponding acetic
acid derivatives (Roche et alo, 1957; Tomita et alo, 1957)0

In vitro studies have shown these derivatives to be present
in skeletal muscle as well as in the liver and kidneye
These findings apparently demonstrate that the oxidative
degradation of thyroxine is possible in all tissues (Albright

are regulated by the effect of

c.

todothy~onines

ho~ovenates

Employing rat liver

on cytochrome

Tipton and Nixon (1S46)

have -J0monstrated that cytochro""!e oxidase activity is decreased
following administration of TSE, desiccated thyroid, or

How aver, o th or workers have been unable to dupl ica.te

th~rroxine"

theso results (Smith and Willtams-Ashroan, l0hg).
difficult to

s~8W

th~t

thyro~1nc

It ts

has a specificity of action

on cytochrome G since adrena.1i::ctomy, lUce \;t1yro1.dectomy, tdll

produce e fall in total body nytocbrome C (Crabkln, 1950b).
Cytoc~rome

oxidase has also teeh shown to oxtd."e

More recently the hypothesis has been presentej that the

a specific oxidative

phc1sphorylati1~;n

thus a 1101-:in<c: +:he

{Lardy and Maley. 1954). 3nd thts may account for the hiaher
basal metabolic rate and

ecreased work efficiency of

hyperthyroid animals (Lar·.:; y, 1957).
found that thyroxine in v-'ttro

Indeed, it has been

;~cpr·e::· ses

the ratio of esterifted;

ioeu high energyy phosphoru2 Lo oxygen (Leblond a.nd Grad,

1948'

Niemeyer~ a.lo~

Hoch and

1951; Martius and Hess, 1951.,1952;

Lipmann 9 1953)0

Diiodothyronine and iodine. but

n)t iodide, have a similar action (Klemperer, 1Q51).

A number of additional facts support this oxidative

10
phosphorylation hypothe si so

Of si gni fic anc e is the recent

observation that mitochondrial s welling and contraction
cycles are induced by thyroxine (Tapley et alo, 1955)0
.

~

Evidence indicates that the mitochondrial swelling requires
electron transport and this effect is promotad by thyroxine
as well as by phosphate, calcium ions, and reduced glutathione,
whereas contraction occurs in the presence of adenosine
triphosphate (Lebninger, 1960).

This becomes important in the

light of the fact that there is a decreased oxygen consumption
in enlarged mitochondria, which is in turn attributed to a
decrease in adenosine triphosphate levels {Aebi, 1952).
However, a great deal of opposition has arisen to the
oxidative phosphorylation hYPothesis since the thyroxine
concentration to produce these effects !!!, vitro is several
orders of magnitude greater than that normally present in

!!!.2.•

In addition, !Q. vitro responses have not been consistent

and sufficiently reproducible (Rawson and Sonenberg, 1959).
Thyroid hormone exerts a significant action on the
mammalian nervous system.

The

ne1~vous

instability of patients

with Graves' disease (exophthalmic goiter) has been noted
since the disease was first recognized (Grave, 1835; Parry,
1835; von Basedow, 1840).

Similarily, the apathy and

sluggishness of cretins has been known for centuries
(Major, 1939).

Furthermore, various psychoses have been

associated with both hyperthyroidism and myxedema (Dunlap
and Moersch, 1935; Jamieson and Wall, 1936).
muscle

reflex~s

Voluntary

are diminished in thyroidectomized animals

11

(Brody, 194la,b), and electroencephalogramg of athyreotic
patients show diminished voltage, slow frequencyj and an
absence of cortical alpha wavesu

In hyperthyroid patients

the alpha rhythm is increased (Bertrand et al., 1938).
Some correlation has been found between the basal metabolic
rate and the rate of alpha wave emanation from the nervous
system (Ross ahd Schwab, 1939).

In contrast to the effects

on general metabolism, most investigators have been unable to

detect a change produced by thyroxine in the

~ate

consumption of brain slices (Harington, 1944)

j

of

oxy~en

n l tbo • ._.h it

is felt that alpha wave frequency measurements during
artificially induced hyperthyroidism are indirect meRsures
of carbohydrate metabolism in the brain

(Rubin~!!.!·'

1937).

Bowman (1925) and Hoskins (1946) found lowered basal metabolic
r~tes

tn a large number of schizophrenic patients.

They also

described unusually htgh clinical tolerance to the effects
of dried thyroide

Brody and Man (1950), however, have

reported normal serum protein-bound iodine levels in similar
patients while Cranswick (1955) has described abnormally
elevated thyroid uptakes of I131 tn a majority of schizophrenic
patients.

The administration of TR.IT to various psycho-

pathologically affected, but

euthyroid, patients evokes the

appearance of formerly latent or absent hostile emotions and
sexual unrest

(Flach~!.!,.,

1960).

Significant emotional

changes, however, were not always observed (Flach!,! al., 1958).
Paralleling the advances in thyroid research, stimulated
by the introduction of radioactive iodine, has been the progress

12

which has been made in neurochemistry as a consequence of the
introduction of iproniazid, a "psyc hic energizer".

This

hydr azine derivative i.1as crir:lnally syntbssized by Roche

Laboratories for LLB chemotherapy of tuberculosis.

It was

soon evident, however, that the greatest value of the drug
lay in its ability to create a sustained feelin g of "wellbeing" in psychieallydepressed patients (Crane, 1956).
3elikoff and others (1953) attributed thi.s effect to central
stimulation.

Zeller~

al. (1952a) discovered that iproniazid

was a potent inhibitor of the intra.cellular enzyme monoamine
oxidase (¥.cA.O), an enzyme incriminated in the mode of action
of certain anti-depressant drugs.
MAO has been found in significant amounts in liver,
kidney, and other organs and tissues (Richter and Tingey,
1939), and is present chiefly in mitochondrial and microsomal
cell fractions (Cotzias and Dole, 1951; Hawkins,

1952).

Enzymatic studies have shown that iproniazid irreversibly
blocks .MAO activity in the autonomic nervous system, brain,
liver, and kidney, both ,,!!! vitro
Barsky, 1952;

Zeller~

and in vivo (Zeller and

al., 1952b).

The psychiatric value of iproniazid and other MAO
inhibitors has been clearly demonstrated and has led to the
introduction of a large number of chemically

hetero~enous

anti-depressants (Delay and Buisson, 1958; Geyer, 1958;
Tobin et al., 1959).

Evidence indicates that MAO is important

in the metabolism of serotonin (5-HT) and the catecholamines,
and that the anti-depressant effects elicited by the MAO

inhibitors are related to the central nervous system changes
in these monoamines (Pletcher, 19579 Udenfr1end et al., 1957;
Spector et alo, 1958)

The relation of HAO to catecholamine

o

metabolism was first recognized by Blaschke et al. (1937)
who demonstrated that the enzyme oxidatively deaminated
epinephrine.

Brodie et

,!!o (1959) have shown that after

single, large, oral doses of MAO inhibitors both S-HT and NE
levels increase stgnificantly in dog and rabbit brain.
However, contrary to previous reports

it has been found that

0-methylat1on probably constitutes the major pathway for the
catabol1sm of this amine

1957).

(Armstrong~ al.~

1956; Axelrod,

MAO has also been incriminated in the metabolism of

tyram1ne and dopamine

- (Spector~.!:..!·,

1958; Resnick, 1959).

It is known that thyroid hormone potentiates the action
of epinephrine on oxygen consumption and basal metabolic rate
(Lardy, 1957), and heart rate (Gravenstein and Thier, 1960).
This potentiatlon of the activity of epinephrine on the
resting blood pressure (Gerlei, 1938) and on isolated arteries
(Smith, 1954) has been explained

a~

the ability of thyroxine

to elicit a fall in tissue amine oxidaae levels.

Likewise,

Burn and Marks (1935) showed that thyroidectomtzed rabbits
were slightly less responsive to epinephrine induced
hyperglycemia than normal animals.

More recent experiments

have shown that feeding of desiccated thyroid causes hepatic
MAO of rabbits to diminish, whereas thyro1dectomy causes MAO
activity to riseo

The rise in blood glucose caused by

injected epinephrine is greater in rabbits fed thyroid extract,

1 r: th:yrc:-1 :Jactomlzed

rabbit~

ha8 been

<
a' 1'1d~-

e1~rlu

'')T'
e.-, ,. ,t l• 1-.
. .~.,c;_r,- ~

ined by the rlse of

7,_··) ..
LC'!",
:_')"'

Dub nick e t. al " ( l '1 6 O) re po r t that r nt live1"
0

.
remain
unc h a~gs~.,

{\.

("ial'k
,j

fl;~i\O

.,,,._

'

1 ')(0 \/

.-.

,

,.,.;

-

(I

act:i.vity is

.

under hyperthyroidism was shown t0 re8ch a minimum only
after twelve days of treatnient,

·;_t:<.\'minatlon of' thyr·oi-:i

feeding allowe.,:. MAO activity tc> retnrn to no1·mal with.in

fourteen days, and consequently the r e versible deerease in
MAO

activity by thyroid hormone v:as con,s ie!ered to be an

indirect suppression of the enzymej perhaps through a
regulation of synthesis of the enzyme o

This supposition

is also shared by others (Ozaki !,! al., l''t/J)"
to the work of Spinks and Burn (1052),

i~

Ir; contrast

has beet shown

that there is no correlation in MAO actJ.v ·L ty andblooc1 suP-2.r

levels in the frog (Smith, 1960).
The distinct psychotropic actions

01

thyroxine and

iproniazid proves interesting when one considers the clinical

thla r 0port ana has reported thg t a

r ~r&~ ~xical

sluggishness supervenes in depressed patients

apathy

~nd

receivln~

both

lnhlhltor action is concerned with tb qi r respective efficacy

~r

t his dise as e, and thi s

salat~:

y

~ nti-ang5nGl

pr0~2dure

cff~cts

Cossio, F;}S9; Schwel.zer,

ai~~r2

t hP

: f lpr sni azid wsre first

195~1; ?',!I asteP d 8,nd

of t he

re~ronss

~epo~ted

Donoso,, 1959).

Several hypothese3 have been p ostu l ated a3 to the mechanism

of tbe

anti~anginal

effects of the Y'..ti.C, in.hiblto:r ,::: "

and Do nc so (1959) find that
myocarG.ia1.

5-B'r,

1pron l~ z1d

flia::ite:r's

0auses ah elevation of

amJ that relief from a n cina 18 mediated

through myocardial and cerebral autonomic nerves"

Ce.sarrrn n

(195 7,1959) proposes that iproniazld may influence cardiac
rn.etaboll s m through some enzyma.t ic mechanism.

Pletcher anc

Pellmont (195fi) have demonstrated tbat a striking ris;;; :tn
Tl'.yocardial catecholami.nes occurs in ipr o r.ti8.Zi.d treated

g t.c '~ea

pig s , and they have related these changea to the the rapeutic

effects. of this compouncL

In certain hypothyroid patients,

however, thyroid in doses as low as eight to sixteen

16

milligrams has produced severe anginal pain.

With concomitant

therapy with an MAO inhibitor, it was found that thyroid
dosage could be gradually increased to relleve the myxedema
without aggravating the cardiovascular complaint (Wolffe and
Shubin, 1959).
The administration of desiccated thyroid has been
shown to elevate the cardiac output whereas myxedematous
patients show a subnormal output (Scheinberg
Hyperthyroidism appears

t~

~

!!·, 1950).

increase the mean systolic

ventricular pressures and the resting blood pressure of
rabbits (Fullerton and Harrop, 1930; Spinka, 1952).

In

contrast, iproniazid regardless of its monoamine sparing
effects, has been shown to cause severe orthostatic hypotenaion
(Randall, 1958) possibly through ganglionic blockade (Gertner,

1959).

It has, for this reason, been suggested for the

treatment of hypertension (Harnes, 1958).

MATERIALS AND METHODS

Subacute Studies
Sixty male, albino rats of the Wistar strain, ranging
in weight from 170-210 g, were divided into 10 groups of

an1mals each (Table 1).

6

Each group was housed separately.

The environmental temperature was maintained between 250-2( 0 c.
Initially, all 60 rats were placed on a control diet conslsttng
of water ad

.l!.£0 and specially repelleted tablets

Laboratory Chow 1 for 7 days.
through V

~ere

of Purina

On the eighth day, groups I

continued on this

c~ntrol

diet while groups

VI through X were placee o n a similar diet which. tn addition,
contained 2 % powdered Thyroid UGSoPo 2 The anim91S were
then maintained on these respective diets for an additional
21 days.

To prevent vitamin A deftctt, due to increased

ut111zatton of this vitamin during the thyroid treatment
(Hague et.!!·• l948) and to retard weight loss (Logaraa and
Drummond, 1938), all animals were given 3 drops or Oleum

Percomorphum 3 (vitamin A and D) orally every tht~d day of
the study.

On the eighth day, normal blood pressure and

blood glucose levels were

taken~

Subsequent blood pressure

levels were recorded daily, and blood sugars were measured
every third day.

-

l Ralston
Purina Coo, Sto Louts 2, M1ssouriv
..
2 Armour Laboratories, Kankakee~ Illinois.

3 Mead Johnson and Coo, Evansville 21, Indiana.
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Diet.

The incorporation of thyroid extract into the

diet was considered the most satisfactory method of hormone
treatment (Anderson et alo, 1943}, although it presented
certain technical difficulties which required the extempoThe food product

raneous repelleting of the animal feed.
as manufactured
meal.

4

contains

no excipient to bind the fibrous

Instead, moisture in the form of steam ls added

directly to the mix, and the moistened meal is forced through
a die under hlgh pressure.

Our facilities dld not permit

high compression tableting so that moisture alone was not
a sutficient adhesive for the fibrous and resilient meal.
Starch, dextrin, sucrose, glucose, lactose, or other
alm1liar carbohydrate-like excipients commonly employed to
prevent crumbling, were inappropriate to use as these would
have a tendency to modify certain metabolic effects of the
thyroid treatment.

A method found simple and expeditious

to produce an acceptable remade chow tablet, using limited
and easily accessible equipment, was to crush the hard,
brittle pellets by use of a Wiley laboratory mt115. passing
the coarse material thence thl'ough a Mikro Samplmt116
(model 579A) to give a number 60 powder or
each 100 g of this powder was

added

40

finer.

To

ml of a warm,

4 Letter from Special Chows Research Division, Research
Department, Ralston Purina (c., St. Louis 2, Missouri.
5 Standard Model Number l, d1str1buted by A.H~ Thomas Coo,
Philadelphia 5, Pennsylvania.
6 Pulverizing Machinery Co., Summit, New Jersey.
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freshly prepared, gelatin-acacia solution made by dissolving
10 g of Gelatin (granular) UaSaPo and l g or Acacia (pmvder)
in 100 ml of boiling

UoS~Po

~!stilled

watere

The

btnder

and powders were then mixed thoroughly to form a damp mass.
The latter was then sifted through a number 10 mesh brass
screen to form granules.

These particles were then passed

through a number 20 mesh screen to obtain a finely

~ranulated

mass.
~o

prepare a 2 % thyroid diet it was necessary to

readjust the formulation so that 100 g of the mass contained

90.76

g

powdered chow, 2.00 g powdered thyroid, and 7.2l+ g

of excip1ent.

These substances were prepared and mixed as

previously described.

Using a hand driven, single punch,

Stokes tablet machine (model A3-Eureka)7 with a 1.27 cm
standard concave punch and d1e set for maximum fill (l.09
cm), the damp granulation was compressed 1nto
tablets having 2.0 mm edge thickness.
punch approximated

7.5

Oo5

g convex

The pressure on the

tons per square inch.

The tablets

were allowed to dry and harden thoroughly at ambient room
temperature (approximately 21°c) for 36 hours or longer.
Drugs.

Eight of the 10 groups of rodents received

daily intraperitoneal injects of a MAO tnhtbttor for the
21 days concomitant with the thyroid or control dtets.
The remaining two groups were used as controls (cf. Table 1).
~nimal

groups I, II, VII, and VIII were injected with

7 FoJ. Stokes Corp., Philadelphia 20, Pennsylvania.

igonicotinyl-2~isopropylhydraz1ne phosphate (1proniazid)8,

a hydrazide enzyme 1nh1b1tor, an
were injected with

gr-oups III, IV, IX, and X

N-benzyl~N-methyl-2-propyrflaJl1ae

hydrochloride (M0-911)9, a non-hydrazide inhibitor, in the
doses as outlined in Table 1.

The structural formulae of

these drugs are given in Figure I-A (Appendix)o

The

solutions tor injection were prepared by dissolving the
respective salts in isotonic saline.
approximated
Methods.

The pH of the solutions

3o5.
Indirect systolic blood pressures were determined

by the method of Kersten et!_!. (1947) ustng a Photoelectr1c-

Tensometer10.

All readings were taken to the oloseet

5 mm Hg

and were recorded as direct instrument values.
Blood glucose levels were determined by the colortmetr1c

.method of Nelson ( 1944) aa modified by Somogyi ( 1945).
Samples were read tn optical density units on a Baueoh and
Lomb Spectrontc 20 colorimeter, type 39-24-10 11, using the
special

!

inch diameter ouvette

facturerl2.

as provided by the manu-

To prevent reading errors, the cuvettea were

calibrated using a standard CUS04 solution.

The colorimeter

was standardized by using known amounts of dextrose diluted
,_

8 Generou~ly supplied as Marsilid by Dr. Robert E.

Dixon, Roche Laboratories, Nutley 10, New Jersey.

9 Generously supplied by Dr. G.M. Everett, Abbott
Laboratories, North Chicago, Illinois.

10 Metro Industries, Long Island Ctty 6, New York.
11 3ausoh and Lomb Optical Co., Rochester, New York.

12 Spectronic 20 test tubes# 33-29-27, Bausch and
Lomb Opttcal Co., Rochester, New York.
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to 100 ml with glass distilled water.

Seven concentrations

were employed and ran8'.ed from 6 0 to 210

mr /110

ml ( T·ab le I-A) .
takin~

Five readinRS of each concentration were made by

1.5

ml of the sample and adding it to

To this mixture was added 0.2 ml of

0.3 N Ba(OH) 2 .

5

0.1

ml of d i s tilled water.
,.,.,,

ry .

("';.o

/o wnu

4

and 0.2 ml of

All chemicals were of reagent quality.

suspension was centrifuged for

5

The

minutes at 4000 rpm's.

One

ml of the s u pernatant ltquid was then pipetted into a Falin-Wu
sugar tube which had been previously fille d with 1.0 ml of
alkaline copper tartrate solution.

The mixture was heated in

boiling water for 20 minutes and tLen c o ol e d in running tap
water for 2 minutes.

To the cooled solution was added 1.0 ml

of arsenomolybdate reagent an d the s olution was
allowe d to stand for approximately 2 minutes.
the v o lume of the resulting colored solution to

nixed and
After

8.a

adjustin~

ml with

distilled water the solution was placed into the cuvette.

A

blank determination was prepared in the same manner usina
0.1 ml of glass distilled water in lie u of the d extrose .
blank cuvette was then placed in

t~e

The

colo r imeter and the

instrument adjusted to an optical density of zero and a wave
length of 500 mu.

The sugar sample was then substituted for

the blank and the resultant optical density read .
of the

5

The mean

readings for each sample was plotte d. a g ainst the

concentration (Table I-A; F igure 1).

The resultant plots

were then adjusted using the line regression metho d as
described by Ostle
line was plotted.

(1956) and the mathematically deriv ed

2

Blood samples were obtained by direct tntracardiac
puncture with a 0.25 ml syringe and a number 27 gauge-!
inch hypodermic needle.

In order to obviate blood samplini:i:

difficulties and possible epinephrine release (Weil, 1952),
the samples were taken while the animals were lightly
anesthetized with pentobarbital sodium (20 mg/kg) .

To

eliminate variances in blood glucose levels, due to
differences 1n the food intake of the animals, all animals
were fasted for 17 noure prior to the blood collections.
The blood samples were processed 1n the aforementioned method
employing a blank with 9ach group ot samples.

The blood

glucose concentration ct eaoh sample was determined from
instrument readings and the respective concentration tn mg/100

ml read from the line graph (Figure 1).
~tstolostc

Studies.

Samples of ltver. kidney, spleen,

and thyroid tissue were remc-11ed from one repreaentat1ve
animal in each group studied.

These tissues were fixed in

Bo11in' s solution, dehydrated, cleared in xylol 9 mounted in

paraffin, and sliced 1.nto 10

ll

sections.

The sections were

stained with hematoxylin and eosin and examined for general
pathology.
Urinarz Dopamine Studies.

Twenty-four hour urine

samples from groups II , V, and X were collected in 2 N H2S04
on the eighth and fifteenth day of the studies.

The pooled

samples were filtered and processed tor extraction of
catecholamines (Crawford and Law, 1958).

An aliquot of the

urine extract was passed through a strongly acidic, cationic

23
exchange resin (Dowex 50W-XB, Na+ form)l3 and the dopamine
was eluted with 8.0 ml of 2 N HCl (Bertler et al., 1958).

Urinary dopamine levels were determined by the trlhydrcxyindole
method of Carlsson and Waldeck (1958) employing an

A~tnco-Bowman

spectrophotofluorometer 14.
Acute Toxicitz Studies

As a consequence of the subacute MAO inhibitor and thyroid
interaction studies, an apparent augmentation was observed in

the mor'te.lttr of hyperthyro1c1 rats receiving high daily
parenteral doses of the h7draztde (tpron1az1d) or the
non-hyd~aztde

(M0-911) enzyme 1nh1bttor (Table 1).

To

evaluate this possible hormonal sens1t1zat1on, 73 male rats
•

{Wiatar strain) ranging in tnttlal weight
employed in an acute mortality stud7.

from 133-190 g were

Four groups of fasted

animals (172 g mean weight), 8 animals to a group, prevtously

-1ntraper1toneally with doses of M0-911 differing by .03 log

fed on a 7 day control diet ad lib.,15 were injected

units (Table

4).

Four other groups (127

~mean

weight),

previously made hyperthyroid by a 7 day desiccated thyroid

--

(2%) ad l1b. d1etl6, were treated in an identical manner.

additional

.

Nine

hyperthyroid rats (130 g mean weight) were injected

solely wlth normal physiological saline solution and served as
controlso

All animals were housed at a temperature of 250-27oc

13

JoTo Baker Chemical Co., Phillipsburg, New Jersey.

14

American Instrument Coo, Inc. Silver Spring, Maryland.

15 Control diet was

studyo

identical to that used in the subacute

16 Thyroid diet was identical to that used in the subacute
study.
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and were provided prior to MAO inhibitor medication with
oral vitamin A and D supplementation at 3 day intervals.

RESULTS
SUBACUTE STUDIES:

General Observations.

The MAO tnhtbttor medicated

antmals exhibited somewhat less motor activtty and seemed
easier to handle than control animals.

Wlthtn 3 to

4

days,

all thyroid fed rodents showed considerable irritability.
whereas the hyperexcitability was less apparent when thyroid
was combined with the enzyme inhibitor me1.Hcation.

The

augmented apathy in ' he latter instances became increasingly
pronounced with continued drug administration.
Food and water consumption decreased with iproniazid
therapy but was less pronounced with M0-911.

Thyroid fed

controls seemed to increase their intake twofold, while
M0-911 and iproniazld

treated, hyperthyroid animals seemed

to be restrained in their feeding habits.

The demise of

drug treated animals was always preceded by complete cessation
of food consumption.

Mean body weights of euthyroid subjects

under iproniazid medication fell steadily while the weights
of animals receiving M0-911 showed either slight decreases or
moderate increases .

Weight decline also occurred in the

hyperthyroid groups; this was
also receiving a MAO inhibitor

1~st

marked in those animals

{Fi~ure

2).

Untreated animals

maintained on the control diet showed normal weight gains.
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Sporadic incidence o f

di E~:c r~1 t:: a

v, as com;non to all t..bt ·

enzyne inhibitor tre n. teu rodcnt ,s nnd wa ... particularly

prevalent in those anina ls re ee i vi nf::; ci0< i cc::-. ted t:.1yrcii do
'I111e feces of t.lAO

inhi~;i

t o r• tre,s. t c:d m 1i :nc,ls were cor..te d with

considerable intestinal 1m1cus.

With iproniazid therapy,

gross observations of urine samples showed considerable
homo i; lobin; blood specimens used for ::;lucose determinations
contained laked erythrocytes.

Reddish colored oc·u.lar

discharges, resembling dried blood, were also regularly
apparent with iproniazid, but they were present less frequently
with M0-911.

An abnormal dec;ree of salivation occurred with

both iproniazid and L0-911 treat;:;rnnts in the euthyroid and
hypertbyroi d animals, but it appeared i;,ore prevalent in those
individuals treated with the latter compoillldu
Subacute Toxicity.
rapidly developedo

Symptoms of' iproniazid toxicity

A muz1ber of e n thyroid rodents given the

250 mt/kg dose of iproniazid died on the second day of
injection and all died within 8 days (Table 1); concur>rent
aclJninistration of thyroid to a similar croup produced
expiration within the 21 clay study period whereas

concolni tant

thyroid feeding and iproniazid treatment resulted in all
deaths within 6 dn:rs o

Al though no deaths followed thyroid

feeding (group V), or K0-911 administration (groups III and IV)
a combination of these substances caused all animals to die
within 15 days (groups VIII and IX).
Tissue Pathologyu

Livers removed from 21 day, iproniazid

treated animals displayed small lesions; kidneys appeared dark

j
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r d whtl

spleens of all the subjects

1

almost black.

Histologic examination of these or ans

aled hepatocellular

damage,

able erythrocyte

onal tubule necrosis, and con

fragmentation 1n the spleen.

Rodents sacrificed after 21

days of M0-911 medication exhibited none of these organic
changes, although several of the spleens appeared dark red
in coloro

Thyroid and M0-911 tissues were unable to te

procuredo
o"~t:l1c

Blood Pressure and Blood Glucose.

Blood preasure

and blood glucose determ1nat1ons are plotted in Figures 3 to

8.

Standard deviations were derived trom

t,

a formulae:

•

J

where Y represents the individual reading, Y the sample mean,
n the sample number, s 2 the variance, and a the standard
deviation with n-1 degrees of freedom (Ostle, 1958).
t-distr1but1on formula {

~

= Y! t

~-r-

A

) was applted to

the normal mean blood pressure and glucose levels of the
sixty samples employed using a t value of 2.660 (Dixon and

Maeseyt 1957).

u represents

the mean value plus or minus

the resultant devtat1on within 99

59

degrees of freedom.

%confidence

limits with

The calculated normal, mean blood

pressure and glucose levels were determined as 110

mm Hg and 104

± 3.87

mg

%respectively.

! 2.65

The standard

blood pressure deviation of the 60 samples was calculated
to be± 7.66 mm Hg and is represented in the figures by the

28
solid, horizontal lines.

The glucose mean standard deviation

was calculated t.o be + 11.20 mg

dashed

%and

is represented by the

All readings, inclusive of the greater

11nes~

percentage of their individual standard deviations, when
present outside of these areas, are noted as statistically

significant changes.
Three week da1ly treatment with either enzyme 1nhib1tor

and/or desiccated thyroid el1e1ted no significant changes in
blood glucose levele, and only tn those animals near death-did
the conoentrat1ons fall (Figures 3 to 8).
Blood pressures were elevated by both thyroid and "MAO
tnhtbttor treatments.
were

witne~sed

Elevattons in mean arterial pressure

with thyroid after

48

hours of feeding, rose

to peak levels by the sixteenth day. with a plateau occurring
at approximately 157 mm Hg.
subject3 after

48

Blood preesures 'f eutbyro1d

hours ot 1p~on1az1d (175 mg/kg) med1oat1on

produced s1gn1f1cant elevattons, followed by a sharp increase
to a peak reading or about 16$ mm Hg within

5 days. Preesures

remained stable until the eighth day when they fell precipitously below normal; readjustment to normal values occurred
by the thirteenth day (Ftgure

4)

even with continued

d~ily

med 1oat1on.

A similar blood pressure pattern was exhibited in M0-911
treated euthyroid rats.

In contrast to 1pron1az1d, M0-911

treatment produced an initial transient hypoteneive effect
lasting 3 to

4 days.

This hypotens1ve pattern appeared

similar at both dose levels, but was of shorter duration at

2 ')
~lfitbin

the 10 mg/ke; dose.

7 to B days of daily

l10~911

treatment blood pressur•es of both d c: s s d "Toups rose to
approximately

155

mm Hg.

This marked hypertensive stnte,

as wlth iproniazid treated subjects, persisted for several

days.

The post-hypertensive pressures with M0-911, however,

did not fall below normotensive levels but stabilized slightly
above the mean normal pressures (Pigm:'es

5

and

6).

Treatment of hyperthyroid animals (3 day thyroid feeding)
with M0-911 produced a marked hypertensive response after 2

days of drug adMinistration, with higher peak systolic
pre ,s sures preva1l1ngtha.n durinc enzyme lnhibi tor or· thyroid

administration alone (Figures 7 and 8).
levels

fel~

Blood pressure

erratically after the eleventh day of treatment,

and all animals expired either on the fourteenth or fifteenth

day.

Ur·inary Analyses.

Urinary dopamine values appeared to

be within normal values in rodents made hyperthyroid by the
21 day feeding of 2

~1'o

desiccated tbyr)id (Table 2).

To the

contrary, however, these values were seemingly elevated in
hypertensive, euthyroid animals treated with daily doses of
iproniazid (175 mg/kg).
at day 15 where

An extremely high value was observed

peculiarly enough the blood pressure values

were within normal limits (Figures 3 and

4).

ACUTE TOXICITY STUDIES
The acute toxicity results are presented in Table 3.
Because a perfect statistical analysis of the respective

LD5o's

was not possible, due to t he limited number of animals

30

employed

and the one group aberrantly r(zponatng to M0-911

at 175 mg/kg, only an

approxi~ation

to this dose for the enzyn:e

inhibitor in the euthyroid animals could be made; this value
was found to be 183.5 ~ 15eO {SoE.) mg/kg by using a graphic

method or analysts (De Beer, 1945).

It should be noted that

in the thyrotd-M0-911 treated group all deaths, save one at
the 152.4 mg/kg level, occurred within 2 hours.

These results

show rather conclusively that the 1ntraperitoneal toxicity of
·M0-911 in hyperthyroid rats ie markedly increased and that the

L.D5 0 or the drug lies well below 152 mg/kg under these
circumstances.
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TABLE l
Results of subacute toxicity experiments
with iproniaztd and M0-911 administered daily
~---·- '111--

of MAO
Inhibitor

Group

D~se

.....

Diet

Deaths

___ --

Iproniazid
2.50 mg/kg

Control

Ipron1az1d
175 mg/kg

Control

M0-911
mg/kg

Control

None

IV

M0-911
10 mg/kg

Control

None

v

None

I

II
III

25

VI
VII
VIII

days

2

%

Iproniazid
250 mg/kg

2 %
Thyroid

Iprontazid
175 mg/kg

Thyroid

MD-911
mg/kg

Thyroid

~5

2 in 21
days

Thyroid

..

All in 8

None

All in 2
days

2

%

All in 6
days

2

%

All in
days

14 I·
I

I

I

IX

x

MO-gll
10 mg/kg
None

2

%

Thyroid
Control

All in 15
days

Mone

l
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TABLE 2

Urinary dopamine levels of iproniazid
and thyroid treated albino rats

,Group

ICollection
Day of

'

ll

I

Dopamine

-~-t-

I

I

Artertal

Blood
Pressure
mm Hg .:!: S.D.

( ag/l)

t

L

Mean

Concentrat 1on

i

I

Urinary

8

I
I
I

.,,. __

I
I
I

j

.

8.5

362

110

~

15

475

112

± 7.9

8

835

i6u

± 13.8

15'

2159

B

482

I

l

I

Control

Dally 1.p.
Ipron1.azld

175 mg/kg

Control Diet

116 + 27.0

-

140

± 9.0

Thyroid (2%)
Fed

!

15

517

161
i

-~·~

.:!:

5.0

I
II

l.
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TABLE 3

Acute toxicity of intraperitoneally
administered M0-911

!

Treatment

Initial
Mean
Weight

I (

g)

I.

M0-911,
1.p.

I

. --

M0-911,

+ Thyroid
( 2%) Diet

t- ---~h71'0

15,3
154
147
151

I

I

I

185

180

163

161
122

'

129

127
129

i

i

II

187 .5

175 .o

163.0

152.4

$0 .0

3/8

37.5

2/8
J

187.5
175.0

163.0
l.~2.4

I
i

!'

8/8
8/8
8/8

8/8

153

130

1.p.

*

25 .o

25.0

All deaths within 2 hr of dosing.

0/9

!'

l

,~---i
1100.0*

100.0*

I

! 100 . O*
·.oo.o

11
i

Diet

Controls

l
I

2/8

id

Normal
Saline

'

4/8

i

+0.14 ml

!

%Deadlt

Response
(12 hrs)

Dose
( mg/kg )

t -~+--+---

----------

-

1.p~

f

165
160
156
153

TI

.
Mean
Weight
1
at
~
1Inject1on1

0

j

• ..l

6.5
6.0

Vl

E-1

~

~
H

~0
~

~

f:l.<t

0

5.5
5.o
4•.s

4.0 ·-·
3.5
.3 .o 2 .51--

2.0

LS
l.O

o.5

...

~-

_,I_ . .L~.~
..
J_,._..l__l _ _ _ _J
30

60

90

100

120

DEXTRtS~

150

180

210

CONCENTRATION

(mg/100 ml)

Ftg. l. Blood glucose standard1zat1on curve.
Mean tnstrument values • ; mean calculated values• •

240

150

"l1

J.40 -

l

L
1

3

5

7

I

I

q

l
11

~

Y OF

l

/
I
l.?

I

I

l.
15

I

I

17

.1

19

I

J
21

TR~A TMENT

Fig~ 2. Graph of mean body wetght e anges oL rats under MAO end/or thyrold medication.
2$ thyro11 die .. •; control
e ~ ; MO-Gl'?. , lOtng lm:'+ control dletA; 1pronla.ztd

(175mg/kg)+ control diet

; MC- 11

lOmg/kg + 2; thyroid dtetA.

210
200
190
p::.,_::i
o~

g<

:>iO
p:; 111

180
170
160

~~
0

150

OH

140

tx.. D
O'l

0

p:: O'l

~~

~s
HH
HH

HH
~~

•

130
120

- - - -+-

""'

100

:

I

110
, I

'

"\- 1•. ~.,

.,-

-"""'-,.._

-~

I

I

----

-r-

..L.

-

~

'

80

1ot-

J
2

""'-:_.-

"'T"'

I
.L..
I
-L.
..J_
._L
- - - · - - - - - - - - - - - - _ _ _ _ _L · - - - - - - - - - - - - - - - - - - - - - - - - · - - - - - - - - - - -

90

.

...,-

:.
-r
--T-.A.-------.A.-------£--------A.
..L

I
4

I·

l

8-

6

10

DAY~OF

~

., 12

14

16

18

TREATMENT

Fig. 3. Bl99d pressure, blood gluco~e, and urinary dopamine levels of rats fed Cl>
tbfroid.
''
Blood pressure•; blood glucose & ; •= 4~ ugfliter urinary dopamine; A= 517 Uf."/liter
urinary dopamine.
~ _.. -~
~

.

,.

.

20

210
200

-

190

•

180
p:: H

o~

l>-t 0

~~
o-........
.p:: i%l

.

f:il t1l

~o

0

~~
{!I
fl)

170
160
150

140

,

l

Ii

_i,

-

>

...

-.-1

130

p:: al

~~

!

A

·- ---

120

~~
HH

-

•-•r
---·-

-·-

... ... "'

- · --·-·
-- --~.......,.~------

···--~

-

'

-

l\

....

- ~· ·-··-

_

i

··-· - " ·"·· J:-:· ·-·
·r~

...:1...:1

HH

::e: ~

i

.;.

80
70 --60 __ _J __ 1 __1._ _ _ _ _ 1
____
2

6

....L

L __ .l__~f_,_J__~· t ___ _J _ ___ L_.. .I -1 _ J_ -- L. - 8

10

12

14

16

18

20

DAY OF TREA:I'MENT

4.-

Figo
Effect of dally 1ntraper1toneal dos~s of iproniazid (175mg/kg) on rat blood
pressure, blood glucose, and urinary dopamine levels.
Blood pressure•; blood glucose•;•= 835 ug/liter urinary dopamine1 h = 2159 ug/liter

urinary dopamine.

210
200
190

180

..

170

~~
>to

. .,,

160

g~

150

I~

140

~-~~,

...........

0

fl:tp

OH
t1l

p::

0

1.30

I

Bs
H...:l

HH

HH

::&:

;

~
T
~-~
·-1 - - · - ___ , · - . - - - - - - · - - t -·-·-···-~·--

120

fll

~~

~

--..-·
I

110

----~-----d=-.

,,

100

....

_L

-1

··~

' .!

--- - --6:'

•

80

-'-

..L

//t -----

i--·---.e.::'~-r.' ------

_,, .,, ,,,

.

•

- -:.._-....:;;...=
-'

y -- -- --· -- - ··- -:---

--"1:;.~ -- - - ---- .. -=.. __

90

l ---···----

. ...L

I

.L

70
60

--.L. --L--1
2

l .-1-1. ___ L -1

4

6

8

t

l
10

J_.
12

t

l

I.

16

18

1
20

DAY OF TREA.TMENT
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Fig; 6c

Effect of dally intraperttoneal doses of M0-911 (lOtng/kg) on rat blood pressure

and blood glucose levels.
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Figo 80 Effect of dail7 intraperitoneal doses of M0-911 (lOmg/kg} + 2% thyroid
feeding on rat blood pressure and blood glucose levels.
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DISCUSSION OF RESULTS
The ostensible reduction of motor activity observed
in the MAO inhibitor medicated rodents, at first glance,
appears contradictory to the clinical evidence indicating
that these compounds are effective psychomotor stimulants
(Loomer~

al., 1957;

Tobin~!.!,.,

1959; Voelkel, 1959}.

One must consider, however, the ability of these inhibitors
to reduce the duration of sleep (Kline, 1958} and produce
insomnia and weakness (Ayd, 1959;

!t !!J..o,

Tobin

1959).

Hawkins~!!·•

1959;

Employment of high, subacute doses can

thus produce a rapid and profound elevation of central
nervous system activity causing generalized body fatigue; a
fatigue condition which would effectively mask its cause.
In the animals where thyroid was
inhibitor medication, fatigue
reflections of apathy.

combtn~d

with

enzyme

and weakness were undoubtedly

This ts a plausible conclusion since

hyperthyroidism itself ts capable of producing tncreased
central nervous system activity characterized by nervousness
and hyperexcttab111ty (Rawson, 1959).
(1956) indicate
degree

or

Although Dongier

~ !.~·,

that . there 1s no correlation between the

anxiety and the rate of thyroid secretion, James

(1941) 1e or the opinion that the level of thyroid activity
does a great deal to determine the relative excitability
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of all nervous processeso_

Again 9 such gross psychomotor

stimulation, incurred through hyperthyroidism, often produces
fatigue and general weakness (Rawson, 1959).

Wang (1927) has

actually demonstrated a depression of spontaneous activity
in rats after two weeks oral medication with desiccated thyroid
which has been attributed to increased fatigue of these animals$
An apparent corollary then is that the increased apathy

observed in hyperthyroid rodents medicated with MAO inhibitors
may be a result of continuous, immense, potentiated central
excitability which brings about a rapid generalized fatigue.
Whether or not this potentiated fatigue occurs through a
combined effect of thyroid and MAO inhibitors upor.. amine
oxidase systems is an intriguing question.
The apparent increa.se in food and v1ater intake of thyroid
fed rats, irr espective of their continued weight lossj agrees
well with the reports of Carlson {1941) and Barker (1951)
but not completely with that of Richter {1933).

No doubt the

use of vitamins A and D as dietary supplements offset, to a
degree, certain of the adverse effects of high doses of the
thyroid substance.

Interestingly, vitamin A has been reported

to protect animals against the rise in oxygen consumption
caused by desiccated thyroid (Sadu and Brody, 1947).
The weight gains ex:perienced with M0-911 medicated
animals correlates well with clinical observations that N.AO
inhibitors produce increased appetites resulting in significant
weight increases (Tobin et alo, 1959)0

On the other hand,

the !eouliar weight loss observed with iproniazid may be a

result of the induced toxic!ty ca.used by the htgh subacute
doses employed (250 and 175 mg/kg).

The combination treatment

with thyroid and inhtbttor 1 which caused both a drastic weight
reduction and loss of appettte, is difficult to interpret,
but tt certainly testifies to a potentiat1on of toxicity.

Toxic manifestations of 1prontaz1d tn euthyroid rodents
were clearly evident as deaths occurred tn both the 175 and
250 mg/kg dose levels during the 21 day study,

Amonr. these

animals a s1gn1!'1eant erythrocyte dastr1iction was observea.
Thie is not surprising in as much as hydrazine and its
analogues are known to possess hemolytic properties.

Benson

--

et al. (1952) have shown that short term iprontazid

administration causes increased destruction and formation

er1throo7tes.

Moreover, histological 1nvest1gat1one of

animals treated with high doses

or

hydr~z1de

1nh1b1tore often

reveal increased erythrocytosis as evidenced by hepatic,
renal, and sp leld;o

hemos!derosis, profuse bone

mar~ow

oellularity, and hyperemia of the spleen ( b1nden and Studer,
1959).

The lack of gross hemolytic change .·

bserved wt th

M0-911 offers added evidence tha.t sueb toxicological syndromes

are most ltkely the result of the hydrazine moiety of
hydrazide MAO inhibitors.
A singular toxioologtcal observation was the apparent
reddish, ocular discharges whioh occurred with subacute
medication with both .iproniazid and M0-911.

This effect has

a parallel ic the report (Gray, 1961) that ocular di s charge
of a porphyrin-like ma terial occurs in rat s under subacute
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medication with etryptamine, a new indole MAO inhibitor.
The feces of ¥.AO inhibitor treated rats were often
coated with considerable mucus.

This observation parallels

the gastrointestinal hypermucosity noted with the psychiatric
use of similar psychic energizers (Sainz, 1959); this side
effect may reflect irritation of the alimentary canal induced
by the medication.
In order to evaluate the possible blood glucose responses
of MAO inhibitors in euthyroid and hyperthyroid rodents, it
became necessary to demonstrate the possible effect of both
a hydrazlde and a noohydrazide inhibitor on blood sugar levels,
particularly since Underhill (1911) has stated that subcutaneous
injection of hydrazine sulphate into dogs produces a fall in
blood glucose wtthin

24 hours.

Also, Underhill (1911, 1914)

reports that this compound when administered to dogs depletes
both liver and skeletal glycogen and prevents glycosuria of
depancreatized animals through inhibition of sugar excretion
by the kidney.

These observations tend to indicate that the

hypoglycemic effect seen clinically with iproniazid medication
(OVConnor et al., 1953; Alexander and Berkeley, 1959; Greenblatt
and Kahn, 1959; Weiss!.,!!.!·' 1959) could be in part the
H H

contribution of the hydrazide moiety (-N-N-) in this compound.
Surprisingly, however, subacute administration of iproniazld
and M0-911 to both euthyroid and hyperthyroid rodents evoked
no significant blood glucose changes.
Of further interest was the lack of significant blood
glucose changes resulting from 2

% desiccated

thyroid feeding.
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treated rodents.

Although extensive investigation tends to support the
hypothesis that iproniaztd ia not a practical ,!!!

~

potenttator of the effects of peripheral E and NE (Cahan
~

!..!:.·, 1953;

Schayer and Smiley, 1953;

Schayer~_!!.,

1953;

Balzer and Holtz, 1956; Kamijo !?,! !!,., 1956; Corne and
Graham, 1957; and others), evidence indicates that breakdown

ot E and NE is depressed in iproniazid treated rats (Schayer,
The resultant peripheral
-vaaopressor effeote of these hormones may, in part, explain

1953; Schayer et al., lq55)§

the h'YJ)ertension.

Goldberg (1959) has reported that

phenlpre.zine, a chemical analogue or 1prontazid. ca1Jses a
marked pressor effect in anesthetized, vagotom1zed dogs when
given

intravenously~

Rodents fed 2% iesiocated thyroid presented no such
1noons1stent vascular effects; the hypertension developed

rapidl7 and was maintained.

This confirms the findtngs ot

Sami7 (1952) with th119oxine tn rats and rabbtts.

Although

hypertension ts not a normally reported syndrome in hyper-

--

thyro1d1sm, Blumgart et al.(1930) have stated that blood
volume increases in this condition.

This together with a

probable increase 1n cardiac output can elevate blood pressures
during thyroid overactivity.

Although 1t is simple to accept

the supposition that elevated cardiac output is primarily a
function of increased metabolism, Rasmussen (1941) declares
that induced hyperthrroidism results in cardiac changes that
cannot be directlr correlated with metabolic rate.

In addition,
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Leblond and Hoff (1944) indicate a possible direct effect of
thyroid on the heart.

Whether these effects are directly

responsible for elevated blood pressures ls difficult to

ascertairiu

A noteworthy observation is the fact that when

thyroid and inhibitor administration are combined in rodents
all hypotens1ve reactions as exhibited with MAO inhibitor
treatment alone are obliterated.
a direct potent1at1on

Whether such responses are

ot combined tnhtbttor and thyroid

treatment requires further 1nvest1gatton.
Stnoe MAO tnhibttors are capable

or

inhibittng a normal

--

oatabol1c pathway or dopamine in vivo (Holtz,

1959~,

one

would expect an increase of this substance in oertatn body
tissues.

After prolonged 1nhtbttor treatment in rodents

(14 days) with high, 1ntraperttoneal doses of tproniazid,
a significant rise 1n ur 1ne.ry dopamine level a did

00011r.

Dopamine acts as a pressor in the rat (Vogt, 19$9), although
it ts decidedly less potent than other cateoholaminea

(Pennefather and Rand, 1960).

Samty (1952) noted that

hyperth7%'o1dism in rats augmented the presaor response to
intravenous doses of d1hydroxyphenylalanine, the precursor

or

dopamine; hts results inferred that this effect was due

to enhanced receptor senstt1vity to the formed dopamine.
Although it was not possible to determine urinary levels of
dopamine from MAO inhibitor treated, hyperthyroid rats 1n the
present experiments, tt might very well be that Se.miy's
findings explain, in part, the rapid onset and marked presser

effects recorded tn these treated animals.

It ts dtffioult,
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on the other hand, to explain the apparent lack of correlation
between high urinary dopamine levels and the pressor responses
in response to high daily doses of iproniazido

It may simply

be a case of cardiovascular adaptation of the drug treated
animalo
The original intention was to administer both ipron1az1d
and M0-911 to both hyper- and euthyroid rats in eqaimolar
concentrations per kilogram or body weight.

Since we

originally employed iproniazid at 250 and 175 mg/kg dose
levels, this necessitated the use or equtmolar M0-911
concentrations at 175 and 123 mg/kg.

In our preliminary

observations, the subaoute administration of M0-911 at these
doses produced total mortality after the second injection.
Subsequent information received from Abbott Laborator1es 17
indicated that subaoute intravenous administration of
and 10 mg/kg or M0-911 was well tolerated in rats.

25

Therefore,

these new doses were utilized and found to be satisfactory.

Of significant interest was the acute and subaoute
potent1ation

or

MAO inhibitor toxicity in hyperthyroid animals.

The administration of desiccated thyroid or thyroxine is known
to modify the susceptibility of animals to the poisonous
effects of a number of substances.

Thyroid hormone increases

the toxicity of alloxan (Houssay and Sara, 1945), cocaine
(Glaubach and Pick, 1931), morphine (Hunt and Seidell, 1910),
dinitrophenol (Glaubach and Pick, 1934), epinephrine

17 Letter from Dr. G.M. Everett, Abbott Laboratories,
Chicago, Illinois.
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(Kroneberg and Huter, 1951; Kroneberg, 1952)j and other
substances.

Large doses of thyroid substance may produce

liver damage (Barker, 1951), and this finds parallel in the
ability of certain MAO tnhibitors to intensify liver damage
caused by certain hepatotox1o agents (Zbinden and Studer, 1959).
However, the cause of the augmented lethality with 1proniazid
and M0-911 is 1ot easily understood. but because of the early
onset of malaise and rapid demtse a direct sensitivity to the
toxic effects to the MAO 1nh1b1tor molecnle per se seems
to be the most likely explanation.

These effects, on the

other hand. may possibly be related to

~.i.AO

1nh1bit1on coupled

or thyroid
feeding (Spinks and Burn, 1952; Zile and Lardy, 1959)

with the similar enz1'fllatic in vivo effects

resulting in an acute liberation of unbound catecholamines,
a diminished ability of the animal to oope with stress, and
a predisposition to fatal thyrotox1cos1s.
psyohothe~apeutic

The reported

1noompat1b111t7 of concurrent MAO 1nh1bitor

--

and thyroid medication (Ba1le1 et al., 1959; Kline, 1961)
may possibly be explained by this hormone induced sensttivtty
to drug toxicity.

SUMMARY AND CONCLUSIONS
l.

The

p~esent

research was undertaken u91ng blood glucose,

blood pressure, and the acute and subaoute toxicity
studies in rodents as parameters, to evaluate the
possible psychotherapeutic ineompattbility which bas

been reported to extst with concu rent thyroid and
~IAO

2.

inhibitor medication.

Datly intraperttoneal lnjactlon of 1pronlaztd or M0-911
for three weeks reduced the spontaneous motor aotiv1ty of
male albino rats.
desiccated thrro1d

3.

Concomitant feeding

or

two

augmented this apathr.

The subacute, tntraperttoneal administration
1pron1aztd or M0-911 in high doses
body weight;

perc~nt

cause~

or

sever

either
loss of

thls weight 1•· es was aggrave.t a bf

concurrent thrrotd feeding.

4.

The sluggishness, aggravated

~etght

decltne. and symptoms

ot malaise from combined thyroid and MAO tnh1.b1.tor
medication may be

or

e~pla1ned

by an increased

sensitivity

hyperthyroid rats to e.cut'e or subacute MAO inhibitor

toxicity.

5.

Limited grose and h1stolog1o observations revealed that
high, dally doses of 1pron1az1d, for three weeks, caused
hepatic and r9nal damage and erythrocyte hemolysts in
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the spleen o

M0-91 l ir

11 ,

parent~ra

l d ,ige:s of ten

or twenty-f1.ve mill tgrams per 'k:tlol!ram did ni.:it p!'oduce
any apparent organic cban -, o, although
was noted

6.

~plenic

darkening

o

In the doses employed, the MAO 1nh1b1tors alone or with

thyroid

treatment, failed to elicit any s1gn1f1osnt

changes 1n blood sugar.

Fead1ng of a two percent th)Toid

diet tor three weeks likewise failed to mod1t1 the blood
glucose picture.

7.

'11 he systolic blood pressures ot' 1p:ron 1e z 1.d treat d, euth

't~o

animals rose significantly above normotenslve levels,
beginning arter forty-eight hours of medication. to a
peak on the eighth day; whereupon they suddenly and
precipitously fell to hypotenstv.e levels.

8.

M0-911, in daily doses of ten or twenty-ftve mtlllgrams
per kilogram body weight, elicited an initial and marked
fall in blood presauree

This response soon gave way in

both instances to a slowly developing hypertenston which
persisted until the tenth or sixteenth day ot

9o

treatment~

The feeding of thyroid substance to H0-911 treated rats
obliterated the 1ntt1al hypotensto

and effected a sharp

pressor response within three daJe

f continued inhibitor

medication.

These pressor effects were greater and more

acute in onset than those noted with either M0-911 or
thyroid administration.

lOo

Urinary dopamine

le~els

following

nA or two week treatment

ot high, daily parenteral doses of 1proniaz1d ro!e about

id
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three f'oldo

The urinary levels of' this biogeni c

catecholamine could not be correlated with pressor
responseso
11 ..

Although admittedly limited in extent$ studies of urinary
dopamine levels did not reveal any increase after three

•

week f'eeding of rats with two percent desiccated thyroid ..
12.

These results suggest strongly that the direct and
indirect pharmacologic actions of iproniazid and
M0-911» given in high daily doses to rats, are aggravated
by a hyperthyroid state; these experimental findings
have obvious clinical

significance~
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It is well-established that the calorigenic, metabolic, and hemodyna.mic
effects of norepinephrine and epinephrine are diminished or lacking in
hypothyroid animals (Sawyer and Brown, 1935; Re.ab, ,1945; Bre'W'Ster, 1956).
On the other hand, although there are some contraindications as to an
enhancement of native sympathomimetic amine activity during hyperthyroidism
(Macmillan and Rand, 1962), thyroid hormone generally potentiates the
action of

~pinephrine

on o:xygen

cons~unption

and basal metabolic rate

(Lardy, 1957), and heart rate (Sawyer and Brmm, 1935; Hoffmann ~ al.,

1957; Gravenstein and Thier, 1960). The potentiation of epinephrine's
activity on the resting blood pressure (Gerlei, 1938; Spinks, 1952) of
rabbits and on isolated swine arteries (Srqith, 1954) and rabbit duodenum
(Trendelenburg, 1953) has been interpreted in terms of a decrease in tissue
monoamine oxidase (MAO) levels or a reduction in the enzyme's activity
engendered by thyroid hormone.
Similarly, Burn and Marks (1925) have found that feeding thyroid to rabbits
increases their sensitivity to epinephrine-induced hyperglycemia.

This

hormonal "priming" effect was later ascribed to the ability of thyroid
hormone to diminish hepatic MAO activity (Spinks and Burn, 1952;
Trendelenburg, 1953).

Although there have been some reports to the con-

trary (Westermann, 1956; Holtz et al., 1956), this in vivo inhibitory
action of thyroid hormone on hepatic MAO in rodents seems reasonably
well-established by the work of Zile and Lardy (1959, 1960), Calvert and
Brody (1961), and Novick (1961).

The hypothesis of Zile and Lardy (1959)

that thyroid hormone regulates the biosynthesis of hepatic MAO has been
supported by others (Ozaki et al., 1960).

-2-

Further, whether the action of thyroid hormone is primarily upon MAO,
0-methyltransferase, or both, the fact remains that the administration
of thyroid elevates catecholamine blood levels and increases their urinary
excretion in animals (Zile and Lardy, 1959; D'Iorio and Leduc, 1960) and
man (Diwani et al., 1960).
Bailey et al. (1959), KJ.ine (1961), and Saunders (1962) have found that
melancholic patients medicated for several d.a;ys with both thyroid and
iproniazid, an irreversible MAO inhibitor and antidepressant, paradoxically
became apathetic a.nd sluggish, ashen and cyanotic in appearance, and
showed evidence of a fall in blood pressure.

These adverse behavioral and

gross physical or somatic effects necessitated withdrawal of the antidepressive agent.

In light of these seemingly peculiar and contradictory effects, the present
investigation was designed in preliminary fashion to determine what action
thyroid feeding had, if a:rry, on the pharmacodynam.ic actions of irreversible
acting MAO inhibitors, and to attempt to explain, at least on a gross
somatic basis, the reason for the reported psychotherapeutic incompatibility between concurrent thyroid and MAO inhibitor medication.
MATERIAI.S AND Mm'HODS
An:imals . -

Sixty male albino Wistar rats, ranging in weight trom 170-210 gm., were
randomly

divi~d

into 10 groups of 6 animals each.

All groups were caged

separately and the environmental temperature was kept between 25-27° C
throughout the study.

-3Drugs and Dosage

Protocol.~

Iproniazid (l-isonicotinyl-2-isopropylhydrazine) phosphate (Ma.rsilid(l))
and pargyline (N-benzyl-N-methyl-2-propynyla.mine hydrochloride; ~10-911;
Eutony1(2)) were used as irreversible MAO inhibitors.

Both drugs were

freshly prepared by dissolving the respective salts in physiological saline
solution.

Injections were given intraperitoneally.

Starting on the eighth

day of drug diet feeding, animal groups I and VII received 250 mg/Kg of
iproniazid phosphate, and groups II and VIII received 175 mg/Kg daily.
Groups III and IX received 25 mg/Kg of pargyline hydrochloride, a.11d IV and
X received 10 mg/Kg daily.

These latter doses were selected because pargy-

line in vitro is almost 8 times (Taylor et al., 1960) and in vivo (intraperi toneally) about 12 times more potent an irreversible MAO inhibitor in
the rodent than iproniazid (Everett, 1962).
The remaining two groups (V f¥1d VI) were not medicated with the synthetic
enzyme inhibitors.
Diet

~Feeding Protocol.~

Control group

v,

which received neither an MAO inhibitor nor thyroid sub-

stance, was given Purina Lab Chow (Ralston Purina Co.)
special retabletted form.

A2

%thyroid

~

libitum in a

drug diet was prepared by homo-

geneously combining desiccated thyroid U.S.P., with the powdered lab chow

(l)Registered trademark of Hoff'mann-La Roche, Inc., U.S.A.
( 2 )Registered trademark of Abbott Laboratories, U.S.A.

-4and retabletting the granulation using suitable excipients.

Incorporation

of thyroid substance into the diet of the rats was felt most suitable in
that it 'WOuld allow gradual medication and continuous absorption to take
place.
Initially, all 60 rats were fed the control diet for 7 days.

On day 8,

groups I through V were continued on this diet while groups VI through
X were fed the thyroid ration.
iproniazid also received 2

'to

Consequently, groups VII and VIII receiving

thyroid, while t;roups IX and X were fed the

thyroid diet and received daily injections of pargyline.

All animals were

maintained on their respective diets for an additional 21 days or, where
fatalities occurred, until the entire group died.

To prevent or retard

vitamin A deficit and weight loss normally evoked by hyperthyroidism, as
well as for purposes of dietary standardization, all an:i.ma.ls were given
orally 3 drops of Oleum Percomorph1..U11 (Mead Johnson) every third day.

The

animals had free access to water at all times.
Histopathologic Studies.-Immediately after death or sacrifice, samples of liver, kidney, and spleen
were removed from one or more representative animals of groups II, III,
IV, and

v.

The tissues were fixed in Bouin's solution and,

a~er

pre-

paration and section (10 microns), were stained with hemato.xylin and
eosin and examined for general morphologic chru1ges.
Blood Pressure Studies.-Indirect systolic blood pressures of each animal were taken daily usinG

-5a precalibrated photoelectric tensometer; the technique of Kersten et al.,

(1947)

was followed.

Fright and other like interfering stresses were

avoided by training a.11 animals to accommodate the pressure cuff before
beginning the drug studies.

Direct instrument values were read in mm Hg;

in no case were they read greater than the closest 5 mm Hg.

When fatalities

due to drug treatment occurred, readings were taken for not less than 3
surviving animals of the particular group.

The normal, mean systolic

blood pressure and standard deviation of the entire

60 rats -was calculated.

Confidence intervals were calculated according to standard statistical
procedures (Ostle, 1954) for the true mean pressure of such untreated
animals.
Urinary Dopamine

Studies.~

Twenty-four hour urine

sa.~ples

from groups II,

in 2N sul:furic acid on the eighth and

v,

and VI were collected

fi~eenth ~s

of drug administration.

The pooled samples were filtered and processed for the extraction of
catecholamines (Crawford and Law, 1958).

An aliquot was passed through

a strongly acidic, cationic exchange resin (Dowex 50W, X-8, Na+ form)
column, and the dopamine was eluted from the resin by 8 ml of 2N hydrochloric acid (Bertler et al., 1958).
by using the

Dopamine concentrations were determined

trihydro~indole-fluorimetric

method of Carlsson and Waldeck

(1958) and an Aminco-Bo'WIIlal1. spectrophotofluorometer (American Instrument
Co.).
Fasting Blood Glucose

Determinations.~

Blood samples were obtained every third day by direct intracardiac puncture

-6and were made, immediately following blood pressure recordings, from
lightly anesthetized (pentobarbital sodium, 20 mg/Kg i.p.) rats.
were fasted for 17 hours prior

t~

the blood sampling.

All animals

Blood glucose concen-

trations for each animal were determined color:Unetrically (Nelson, 1944;
Somogyi, 1945) using a precalibrated Spectronic 20 color:Uneter (Bausch and
Lomb) and 12.7 mm diameter cuvettes.

Individual concentrations were read

as optional density units, and these were transfonned into mg/l(X) ml by
referring to a calibration curve.

The individual values were averaged to

obtain group means, and standard deviations were calculated.

Confidence

intervals, as before, were calculated for the true, untreated, rat mean
blood glucose concentration.
RESULTS

General

Observations.~

The MAO inhibitor-treated animals exhibited a somewhat diminished random
motor activity and were easier to handle than unmedicated controls.

Within

3-4 days, all thyroid-fed rats became considerably irritable, but in those
groups 'Where both enzyme inhibitor and thyroid were administered the hyperexcitability vas less apparent.

In fact, the sluggishness and asthenia of

these dually medicated animals became increasingly pronounced as the drug
treatments continued.
Food and water consumption was generally decreased in the MAO inhibitortreated groups, but this effect was less pronounced with the pargyline
treatments • Thyroid-fed animals ate and drank avidly, 'While hyperthyroid
rats given either of the enzyme inhibitors seemed restrained in their

-7feeding habits.

Death of the MAO inhibitor-treated animal.s was always

preceded by complete inanition.

Mean body weights of euthyroid rats

under iproniazid medication fell steadily especially during the first 9
da\Y's of injection, while the body weights of similar animals under pargyline
showed either slight decreases or moderate increases.

A relatively slow,

but progressive weight decline also occurred in the thyroid-fed rats
an initial 5-day increase.

a~er

Untreated animals maintained on the control

diet showed nonnal weight gains, and at the end of 3 weeks weighed, on the
average, 45 gm more than the hyperthyroid control animals.

A sporadic

incidence of diarrhea was common in all enzyme inhibitor-treated rats;
it was particularly evident in thyroid-fed animals.

The feces of MAO

inhibitor-treated rats were coated with considerable intestinal mucus.
Considerable blood was noted in urine samples from iproniazid-treated rats;
blood specimens contained laked erythrocytes.

Iproniazid-medica.ted rats

regularly showed reddish-colored ocular discharges that resembled dried
blood; this effect was less frequently observed with pargyline.

An ab-

normal degree of salivation occurred with both iproniazid and pargyline
treatments in euthyroid and hyperthyroid animals, but this effect appeared
more prevalent with the nonhydrazine compound.
Subacute

Toxicity.~

Symptoms of iproniazid toxicity rapidly developed.

In group I, given

250 mg/Kg of iproniazid daily, a few rats died on the second da\Y of injection; all animals of this group died within 8

~s

(Table I).

-8-

[Table I Here)

'l'he lower dose of iproniazid (175 mg/Kg) was considerably less toxic.
feeding of 2

%desiccated

'l'he

thyroid concurrently with injected iproniazid at

both dose levels (groups VII and VIII), however, hastened their deaths

3- to 4-fold.

Although the feeding of thyroid alone (group VI) or the

administration of pargyline at 10 (group IV) and 25 mg/Kg (group III)
alone caused no fatalities, the concurrent administration of both thyroid
and MAO inhibitor (groups IX and X) resulted in the deaths of all animals
within 15 deys.
Histopa.thologic

Studies.~

Livers removed from rats 'Which had received iproniazid for 21 deys showed
small superficial lesions.

The kidneys of these animals appeared abnormally

dark red in color; spleens, on the other hand, were almost black.

Histo-

logic examination of these organs revealed hepatocellular damage, renal
tubule necrosis, and considerable erythrocyte fragmentation in the spleen.
Rats sacrificed after 21 de\Ys of pargyline dosing exhibited none of these
tissue changes; several of the spleens in these groups, however, appeared
abnormally dark red in color.
animals were not examined.

Tissues from thyroid-MAO inhibitor-treated

Table I
SUbacute Toxicity in Rats of Desiccated Thyroid, Iproniazid,
and Pargyline, Alone and in Combination

Group
I
II

Daily Intraperitoneal Dose
of MAO Inhibitor (mg/Kg)

Diet

Deaths

Iproniazid ro
4
250

Control

All within 8 days

ro 4

Control

2 within 21 days

Iproniazid
175

III

Pargyline HCl
25

Control

None

IV

Pargyline HCl
10

control

None

v

None

Control

None

VI

None

2

%Thyroid

None

'fa

VII

Iproniazid
250

P(\

2

Thyroid

All within 2 days

VIII

Iproniazid
175

ro4

2 'fo Thyroid

All within 6 days

IX

Pargyline HCl
25

2

%Thyroid

All within 14 deys

x

Pargyline HCl
10

2

%Thyroid

All within 15 days

-9Blood Pressure and Urinary Do;pamine

Studies.~

The normal, mean systolic blood pressure and standard deviation (S .D.)
of the 60 rats were calculated to be 110.::, 7.66 mm Hg.

Confidence limits

(99 i) of 107.4-112.6 mm Hg were calculated for the true mean in the untreated rats.
It can be seen from Figures 1-l+ that a slight time factor exists in the
response to drug or thyroid treatments.

Moreover, most animals in the MAO

inhibitor groups did not show synchronous changes in blood pressure so that
the intragroup variability, for any given day,
than that observed in control

~r

was.

generally more marked

pretreatment periods.

Therefore, the

following very conservative statistical procedure and reasoning was adopted:
the S.D. of the mean of a sample of 6 animals, drawn from the same population as the 60 control observations, -would be the S.D. of the general
:population divided by the square root of 6, i.e., .2.4495.

Any

mean of a

sample of size 6 that differed from the :population mean by more than 2.58
times the S.D. divided by 2.4495 -would be significantly different at the
1

i

level.

When, as in the

the estimated value

pr~sent

(7 .66 mm Hg)

situation, the true S.D. is not knoYin,

may

be used if the normal distribution

critical value of 2. 58 is replace"d by the critical value of Student's "t"
with the appropriate number of degrees of freedom, i.e., d.f.
"t"

= 2.660.

= 59;

Thus, making the conservative assumption that the true mean

is as likely to be at the upper boundary of the conf'idence interval as at
its center, a;ny mean of a sample of 6 that lies outside the calculated confidence interval by more than 2.66o times the S.D. divided by 2.4495 is
significantly different from the true mean of the control :population,

-10at the 1
mean.
Sf3¥

~

level, if indeed the confidence interval does contain the true

Since we have 99

<{o

confidence that it does contain the mean, we can

with not less than 98.0l

%confidence

that a:ny such outlying small

sample (6) mean comes from a population other than that of the untreated
rats, and is, therefore, a true difference.

Applying these calculations,

98 tfo "critical limits" were determined for the control mean blood pressure
and are represented by the continuous, horizontal lines in Figures 1-4.

The 24-hour pooled urinary dopamine concentrations of the nonmedicated
controls (group V) _were estimated on df3¥s 8 and 15; these quantities were
found to be 362 and 475 pg/l of urine respectively.
these amounts are considered representative.

In our laboratory,

The mean arterial blood

pressures taken on these same fucy"s were 110 + 8.5 and 112 :t 7.9 mm Hg
respectively.
As shown in Figure 1, iproniazid at the 175 mg/Kg daily dose level (group

II)

unifo~

caused statistically significant presser effects a.f'ter fucy" 1.

(Figure 1 Here]

Blood pressures continued to rise until df3¥ 5 when
~

they plateaued.

On

9 and 10, the systolic pressures fell precipitously and, except for

a rise on df3¥ 11 of treatment, became rather erratic and remained only
barely above or within normotensi ve levels for the remainder of the treatment period.

The urinary dopamine le·ve1 for this same group was almost

-11twice the normal on day 8.

On day 15, were the mean blood pressure, sur-

prisingly enough, was almost normal (116 ~ 27.0 mm Hg), the excretion was
approximately 5 times greater than customary.
The blood pressure effects of pargyline at the 25 mg/Kg daily dose level
are shown in Figure 2.

[Figure 2 Here]

In contrast with iproniazid, pargyline produced an initial, transient

hypotensive effect that reached a maximum on day 3.

After day 6, mean

pressures rose for 3 days and attained a mean peak of about 155 mm Hg on
day 9.

Pressures fell on day 10, but they stabilized slightly above

normotensive levels thereafter.

At the lower dose (10 mg/Kg daily, group

IV), pargyline elicited somewhat similar blood pressure effects, but the
mean, peak presser effect (163 mm Hg) did not occur until day 13.

On

days 16 and 17, mean pressures fell to about 127 mm Hg, Vlhereupon a
presser effect (up to 145 mm Hg) again supervened on day 18 that persiste~

until the end of the treatment period.

The feeding of desiccated thyroid caused a definite, gradually developing
presser effect first noted on day hj peak pressures of about 160
occurred on da\)" 16 (Figure

3).

mr:i.

Hg
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[Figure 3 Here]

Individual blood pressures in this group were much less variable than in
a:ny of the MA.O inhibitor-treated animals.

There was no evidence of a

return to normotensive levels while thyroid feeding was continued.
Irrespective of the pressor responses, pooled dopenine excretion values on
days 8 and 15 were 482 and 517 pg/l of urine respectively.

These values

for the thyroid-fed group were not considered abnormally high.
The feeding of 2

%thyroid

to iproniazid-medicated animals (groups VII and

VIII) decimated the respective groups in such rapid fashion (Table I)
that the recording of the erratic blood pressures and blood glucose concentrations was made almost impossible and gave little basis for interpretation.
Figure 4 shows the blood pressure effects in rats treated with 25 mg/Kg of
pa.rgyline and 2 ~ thyroid.

[Figure 4 Here]

It is obvious that although the variation in blood pressures among the
individual animals of the group was large, a definite presser effect began

-13after the second

a.nd, except for a fall on day 9, was maintained until

da.y

day J2 when the blood pressures of the surviving animals of the group fell

sharply thereafter to nonnotensive or slightly hypotensive levels.

No

evidence of any initial transient fall in blood pressure as in the pargylinetreated rats was detected.
The collateral treatment of rats with 10 mg/Kg of pargyline and 2

%thyroid

gave effects roughly equivalent to the higher dose of pa.rgyline and thyroid
feeding.

The peak mean pressure occurred on

da.y

6 and thereafter fell

slowly, but erratically, to a minimum of 88 mm Hg on day 12.
pressures stabilized at about 105 rrun Hg

therea~er.

The blood

The entire group died

between deys 14 and 15.
Fasting Blood Glucose

Studies.~

The blood glucose mean and standard deviation of the
ments were calculated to be 104 :!: 11.20 mm °fo.
of 107.9-100.1
rats.

mg%

60 control measure-

Confidence limits (99 ~)

were calcul.ated for the true mean in the untreated

Employing the same statistical reasoning as adopted for the blood

pressure studies, the 98

%"critical

limits" were determined for the

control mean and a.re represented by the broken, horizontal lines in Figures
1-4.
AB readily evident from the figures, 3-week daily treatment with either

one of the enzyme inhibitors and/or desiccated thyroid generally failed
to statistically mod.i:f'y mean blood glucose concentrations although fluctuations did occur; only in those animals near death from MAO inhibitor
treatment did the concentrations fall.

-14DISCUSSION
Although not quantitated, both hydrazide and nonhydrazide f>'IAO inhibitors
in the doses employed did not elicit any gross evidence of hyperexcitability
or an increase in general random motor activity.

Certainly one explanation

for the generalized depression of activity may be simply a reflection of
subacute toxicity.

The hyperirritability of the hyperthyroid rats, as

well described by a number of other workers (French, 1912; Watanabe and
Nomura, 1937), was completely reversed in those animals receiving both
thyroid and an Ml\O inhibitor.

The somato-motor weakness and sluggishness

of these animals most likely is a reflection of general apathy and

a..~

index of an accelerated toxicity in animals whose general metabolisn has
already been seriously disturbed.
The general increase in food and water intake of the thyroid-fed rats,
irrespective of their hampered weight gains, agrees with the reports of
Carlson~~· (1912), French (1912), and Barker (1951); these effects

are undoubtedly accounted for by an increased metabolic rate and the constant need to satisfy such a demand.

No doubt the collateral use of

vitamins A and D offset, to an extent, some of the adverse effects of
high doses of thyroid.

The exaggerated weight decline in the animals

dosed with both hormone and an MAO inhibitor is most likely a nonspecific
symptom of drug-induced toxicity.
The diarrhea noted in almost all thyroid-fed rats is a commonly observed
untoward effect (gastrointestinal hypermotility) in thyroid-sensitive
animals (Carlson et al., 1912; French, 1912).

The marked diarrhea in

-15the MAO inhibitor-treated rats is difficult, however, to reconcile with
the frequently reported constipating effect of iproniazid in man (O'Connor
et al., 1953; Alexander and Berkeley, 1959; Weiss et al., 1959).

The

elimination of fecal matter coated with mucus was also a common finding
in the iproniazid- and pargyline-medicated rats.
reported with the clinical use of other

~..AO

Hypermucosity has been

inhibitor antidepressants

(Sainz, 1959); this side effect in both man and rat may possibly indicate
incipient gastroenteritis.
Hematuria and the presence of laked erythrocytes were commonly found in
blood samples from iproniazid - but not pargyline-treated rats.

The

hemolytic effects of hydrazine and its analogues are -well-documented,
and the above toxicity -we observed may be related to the hydrazine moiety
of iproniazid.

Hemolytic anemia has only rarely been reported to occur

in man ( 0 'Connor et al., 1953) with iproniazid use.

Moreover, histo-

pathologic studies in other rodents medicated with relatively high doses
of hydrazides have shown signs of increased erythrocyte destruction, as
evidenced by hemosiderosis of the kidney, liver, and spleen, and hyperemia or darkening of the latter organ (Benson et al., 1952; Zbinden and
Studer, 1959) .

These reports, the hemolys is noted in our stuay, and the

reported hepatic and splenic accumulation of iproniazid

a~er

parenteral

administration (Koechlin and Iliev, 1959) may explain the organ darkening
and injury observed by us.

The lack of gross hemolytic changes with

pargyline contributes presumptively to the impression that such toxicity
is most probably due to the hydrazine moiety of iproniazid.

A rather

singular toxic effect was the reddish ocular discharges (chromodacryorrhealike) that occurred with subacute administration of both iproniazid and

-16pa.rgyline.

The only comparable effect,

knO"Wil

to us, is the report of an

ocular discharge of a. porphyrin-like material in rats given subacute doses
of etrypta.mine acetate, a. new indole MAO inhibitor {Gr~, 1961).
The rapid onset of ipronia.zid toxicity was not particularly surprising
as the intra.peritoneal doses used -were very high.

What "Was unexpected,

however, were the rapidity and high incidence of fatalities in the simultaneously enzyme inhibitor- and thyroid-medicated rats.

The administration

of desiccated thyroid or thyroxine is knovin to modif'y the susceptibility
of animals to the toxic effects of a number of drugs.

Although large

doses of thyroid !lla\Y.produce liver damage (Barker, 1951), the rapid onset
of toxicity and high incidence of fatality in those animals receiving
either one of the synthetic MAO inhibitors and thyroid seems to imply that
the metabolic effects of the latter accentuate the direct, subacute toxicity
of large doses of the antidepressants.

This assumption is :f'Urther strengthened

by our previous findings that hyperthyroidism increases the a.cute toxicity
of pe.rgyline in rats (Carrier and Buday, 1961) .
acute or subacute, are in

a;ny way

Whether these toxic effects,

related to a. combination of the in vivo

MAO inhibitory effects of thyroid hormone and the synthetic enzyme inhibitors with a. resultant

elevation of catecholamines {Leduc

~

al.,

1955; Zile and Lardy, 1959) or serotonin (Put and Hogenhuis, 1962), no
conclusion can be dra."W?l at this time; further work {behavioral and enzymatic),
however, is in progress to study these possible causal relationships.
a;ny

event, the stress of impending thyrotoxicosis in the MAO inhibitor-

trea.ted animals in our study may, in some superficial fashion, parallel
the clinical reports of a pharmacothera.peutic incompatibility during

In

-17simultaneous medication with thyroid extract and irreversible MAO inhibitors
(Bailey et al., 1959; Kline, 1961).

--

The blood pressure responses to prolonged administration of both iproniazid
and pargyline showed la,rge variations and wcy- be explained on the basis of
oscillating responses and the small sample size.

Because of the great

dose difference between iproniazid and pargyline, little comparative
importance can be given to the latter drug's minor primary bypotensive
effects • What is perhaps of some importance is the fact that a pressor
effect induced by repeated dosing with both drugs did occur.

flY:pOtension

is a common side effect during protracted medication with .the MAO inhibitors
and when given acutely to animals in relatively low doses (Cahn and Herold,

1962).

Single, massive parenteral doses of iproniazid, however, cause a

rise in rabbit blood pressure (De Palol and Lemberg, 1962).

Dopamine, the

biogenic precursor of norepinephrine and epinephrine, is a weak pressor
material in the rat (Vogt, 1959).
by MAO inhibitors

(Horwitz~

Its metabolism is reduced or blocked

al., 1962), and we speculated that the

pressor effects persisting from the second to eighth day with iproniazid
dosing might be correlated vith the urinary

excr~tion

No such correlation was able to be made, however.
values were elevated approximately 100

~

of the catecholamine.

Dopamine excretion

on day 8 'When the mean systolic

blood pressure was some 55 mm Hg above the normal, but on day 15, 'When
dopamine excretion values were increased about 400

%,

the mean blood pressure

was within normal. limits.
Hypertension is a frequent concomitant of clinical hyperthyroidism (Logan,

-181930).

In rats, thyroxine-induced hypertension was explained by Samiy (1952)

as due to an altered receptor sensitivity to dopainine.
"W8.S

Dopamine excretion

not significantly elevated in our thyroid-fed rats, however, and hence

the presser effects in the hyperthyroid rats may have no relationship to
this catecholamine.

Furthermore, hyperthyroidism inhibits hepatic dopa

decarbo.xylase, the enzyme responsible for the rapid conversion of 3,4dihydro.xyphenylalanine (dopa) to dopamine (Clark, 1959).

Considering this,

and the avidity of MAO for dopamine, it is tempting to speculate about
these mutua.l.ly antagonistic properties of thyroid hormone on those enzymes
plEcy'ing a significant role in the biotransformation of dopamine and the
reason for the normal dopamine excretion values in hyperthyroid rats.
Whereas the daily injection of pargyline alone uniformly elicited a slight,
primary depressor response la.sting as long as the fourth da¥ of medication,
the administration of pargyline to thyroid-fed rats obliterated this
initial effect; a presser effect was evoked a.s early as dEcy' 3 and although
temporary, the presser effects were somewhat greater than that with either
hormone or drug given alone.

The sudden and precipitous fall in blood

pressure occurring on da¥s 11 and 12 in those groups (IX and X) receiving
both pargyline and thyroid cannot be readily explained.

Certain.4" cardio-

vascular collapse, a prelude to death, is a possibility.
Parenteral administration of hydrazine sulfate in large doses elicits

hypo-

glycemia in animals (Underhill, 1911), and clinical reports of diminished
blood glucose levels during iproniazid therapy have been published (Weiss
~

al • , 1959; Aksel, 1960) •

Contrary to expectations, however, no statistically

-19significant blood glucose changes occurred with iproniazid; no significant
changes occurred with pargyline.

Similarly, thyroid feeding elicited no

blood glucose changes in rats; ordinarily the feeding of large quantities
of thyroid to dogs and rats (Houssay, 1944) or hyperthyroidism in man
(Geyelin, 1915) results in a definite hyperglycemia.

The reason for our

inability to duplicate these effects in our study is obscure.
SUMMARY

Daily intraperitoneal injections of massive doses of iproniazid phosphate
and high doses of pargyline hydrochloride for as long as three weeks markedly
reduced the general motor activity and body weight of male rats.

Both of

these effects, the general malaise, and the incidence of mortality was
increased by the daily feeding of a high concentration of desiccated thyroid.
Limited gross and microscopic studies showed that iproniazid (175 mg/Kg
daily) caused hepatic, splenic, and renal injury, and hemolysis.

Pargyline

(10 and 25 mg/Kg daily), other than causing splenic darkening, showed no
comparable effects.
Although exhibiting large fluctuations, systolic blood pressures rose
rapidly, but only temporarily, in iproniazid-treated rats.
presser effects in pargyline-dosed rats began only after

Significant

7 days. The

collateral feeding of thyroid to pargyline-treated animals accelerated the
onset and accentuated the presser effects.

.

The feeding of thyroid alone

elicited a slowly developing and uniform presser effect.

Limited dopamine

studies in normal, iproniazid- and thyroid-medicated rats showed that there
was no apparent correlation between the presser responses and the excretion

-20-

of dopamine.

No significant changes in fasting blood glucose concentrations

occurred during subacute administration of the MAO inhibitors or thyroid
alone, nor when the treatments were concurrent.

-21-
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A method found
remade~chow

sim~le

and expeditious to produce an acceptable

tablet, using limited and easily accessible equipment, was

to crush the hard, brittle pellets by use of a Wiley laboratory mill, passing
the coarse material thence through a Mikro Samplmill (model 579A) to
give a number 60 powder or finer.

To

ea~h

100 g of this powder was

added 40 ml of a warm, freshly prepared, gelatin-acacia solution made by
dissolving 10 g of Gelatin (granular) U.S. P. and 1 g of Acacia (powder)
U.S. P. in 100 ml of boiling distilled water.

The binder and powders

0

were then mixed thoroughly to form a d amp mass.

The latter was then

sifted through a number 10 mesh brass ·screen to form granules.

These

particles were then passed through a number 20 mesh screen to obtain
a finely granulated mass.
Using a hand driven, single punch, Stokes tablet machine (model
A-3 Eureka) with a 1. 27 cm standard concave punch and die set for
maximum fill (1. 09 cm), the damp granulation was compressed into
O. S g convex tablets having 2. 0 mm edge thickness.
punch approximated 7. S tons per 1 square inch.

The pressure on the

The tablets were allowed

to dry and harden thoroughly at ambient room temperature (approximately
21°c) for 36 hours or longer.

